Eli Lilly Aktie
WKN: 858560 / ISIN: US5324571083
29.10.2018 13:11:21
|
Dicerna Stock Surges On RNAi Deal With Lilly
(RTTNews) - Eli Lilly and Company (LLY) and Dicerna Pharmaceuticals (DRNA) announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain.
In the Monday's pre-market, DRNA is trading at $17.72, up $4.72 or 36.31 percent.
The companies will utilize Dicerna's proprietary GalXC RNAi technology platform to progress new drug targets toward clinical development and commercialization.
In addition, the partners will collaborate to move beyond the current technical paradigm in order to generate next-generation oligonucleotide therapeutic agents.
RNA interference (RNAi) is an emerging new approach to drug discovery, focused on a biologic process in which certain RNA molecules inhibit the expression of disease-causing genes by destroying the messenger RNAs (mRNAs) of those genes. RNAi has the potential to treat diseases by silencing some of the most well-validated, yet previously inaccessible drug targets.
As per the terms of the agreement, Dicerna will receive an upfront payment of $100 million, as well as an equity investment of $100 million at a premium. Dicerna is also eligible to receive up to about $350 million per target in development and commercialization milestones, as well as tiered royalties ranging from the mid-single to low-double digits on product sales.
Dicerna will work exclusively with Lilly in the neurodegeneration and pain fields, and on select targets in cardio-metabolic diseases. The two companies anticipate collaborating on more than ten targets.
The transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. The transaction will be reflected in Lilly's reported results and financial guidance. There will be no change to Lilly's 2018 non-GAAP earnings per share guidance as a result of this transaction, Eli Lilly said.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
20.05.25 |
S&P 500-Wert Eli Lilly-Aktie: So viel hätten Anleger an einem Eli Lilly-Investment von vor 10 Jahren verdient (finanzen.at) | |
13.05.25 |
S&P 500-Titel Eli Lilly-Aktie: So viel Gewinn hätte ein Investment in Eli Lilly von vor 5 Jahren abgeworfen (finanzen.at) | |
08.05.25 |
Aufschläge in New York: S&P 500 verbucht am Mittag Gewinne (finanzen.at) | |
08.05.25 |
Donnerstagshandel in New York: S&P 500-Börsianer greifen zum Handelsstart zu (finanzen.at) | |
06.05.25 |
S&P 500-Titel Eli Lilly-Aktie: So viel Gewinn hätte ein Investment in Eli Lilly von vor 3 Jahren abgeworfen (finanzen.at) | |
01.05.25 |
Gewinne in New York: S&P 500 legt schlussendlich zu (finanzen.at) | |
01.05.25 |
Eli Lilly-Aktie mit kräftiogen Verlusten: Gewinnziel gesenkt - Eli Lilly muss Abschreibungen verbuchen (dpa-AFX) | |
01.05.25 |
Pluszeichen in New York: S&P 500 zeigt sich am Donnerstagnachmittag fester (finanzen.at) |
Analysen zu Eli Lillymehr Analysen
20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Eli Lilly | 642,10 | 0,36% |
|